The Hippo signaling pathway in leukemia: function, interaction, and carcinogenesis

Abstract

Cancer can be considered as a communication disease between and within cells; nevertheless, there is no effective therapy for the condition, and this disease is typically identified at its late stage. Chemotherapy, radiation, and molecular-targeted treatment are typically ineffective against cancer cells. A better grasp of the processes of carcinogenesis, aggressiveness, metastasis, treatment resistance, detection of the illness at an earlier stage, and obtaining a better therapeutic response will be made possible. Researchers have discovered that cancerous mutations mainly affect signaling pathways. The Hippo pathway, as one of the main signaling pathways of a cell, has a unique ability to cause cancer. In order to treat cancer, a complete understanding of the Hippo signaling system will be required. On the other hand, interaction with other pathways like Wnt, TGF-β, AMPK, Notch, JNK, mTOR, and Ras/MAP kinase pathways can contribute to carcinogenesis. Phosphorylation of oncogene YAP and TAZ could lead to leukemogenesis, which this process could be regulated via other signaling pathways. This review article aimed to shed light on how the Hippo pathway interacts with other cellular signaling networks and its functions in leukemia.

mIR-99a-5p and mIR-148a-3p as Candidate Molecular Biomarkers for the Survival of Lung Cancer Patients

“…The enrichment of cancer-related pathways, including small cell lung cancer (SCLC), pancreatic cancer, chronic myeloid leukaemia (CML), Hippo and sphingolipid signalling pathways, offers valuable insights into the potential mechanisms involved in the development and progression of cancer. The Hippo and sphingolipid signaling pathways regulate cell proliferation and can serve as potential targets for treating various carcinoma cancers by either promoting tumor suppression or survival (Han, 2019;Ogretmen, 2018), as reported in LUAD (Wang et al, 2015), breast (Wei et al, 2018), pancreatic (Wu et al, 2021), and leukaemia (Noorbakhsh et al, 2021). Our findings suggest that the target genes are also associated with the Hippo and sphingolipid signalling pathways, which may impact the survival of patients with LUAD.…”

Yes-associated protein-1 overexpression in ocular surface squamous neoplasia; a potential diagnostic marker and therapeutic target

“…YAP-1 protein is overexpressed in various cancers, including colorectal cancer, gastric cancer, hepatocellular carcinoma, breast cancer, hedgehog-associated medulloblastoma, esophageal and oral squamous cell carcinoma (SCC), leukemia and other solid tumors ( 7 , 8 , 12 – 35 ), and has been referred to as an oncogene.…”

Deficiency of Cbfβ in articular cartilage leads to osteoarthritis-like phenotype through Hippo/Yap, TGFβ, and Wnt/β-catenin signaling pathways

“…On the one hand, we speculate that this difference might be caused by the change of Yap expression in cartilage joints. It is worth noting that the Hippo/Yap pathway is closely related to the Wnt/β-catenin pathway 49 , 50 . Yap is a key regulatory molecule in the Hippo signaling pathway, and Yap activity is necessary for tissue regeneration after tissue injury 51 .…”